.png)
Agenzia Italiana del Farmaco
The AIFA Board of Directors examined and approved 38 dossiers for which the Scientific and Economic Commission for Medicinal Products (SEC) completed the assessment process (Annex 1).
AIFA has published the updated weekly data concerning treatments with new second-generation direct acting antiviral agents (DAAs) for chronic hepatitis C, as collected by AIFA Monitoring registries.
AIFA makes available, to healthcare professionals, a list of class A and H medicinal products dispensed by the National Health Service, sorted by active ingredient and trade name.
AIFA has published the updated weekly data concerning treatments with new second-generation direct acting antiviral agents (DAAs) for chronic hepatitis C, as collected by AIFA Monitoring registries.
